Skip to search formSkip to main contentSkip to account menu

duvelisib

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

IPI-145

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Oral Duvelisib Potential New Option for Indolent Non-Hodgkin Lymphoma
The DYNAMO study investigated the oral PI3K gamma inhibitor duvelisib in heavily pretreated indolent non-Hodgkin lymphoma… 
2019
2019
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
2019
2019
PS1160 PATTERNS OF DUVELISIB-INDUCED LYMPHOCYTOSIS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA INCLUDING THOSE WITH HIGH-RISK FACTORS TREATED IN THE…
Review
2018
Review
2018
Duvelisib Granted Priority Review for R/R CLL/SLL and FL
In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively. 
2018
2018
Effect of dual PI3K-δ,γ inhibitor duvelisib on immunosuppressive Tregs and myeloid cells to enhance efficacy of checkpoint and co-stimulatory antibodies in a B cell lymphoma model.
33Background: Duvelisib is a dual inhibitor of PI3K-δ and PI3K-γ which has shown clinical activity as monotherapy in CLL/SLL, FL… 
2018
2018
Dual PI3K Inhibitor Duvelisib Prolonged PFS in Advanced CLL
Duvelisib improved the median progression-free survival of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma… 
2017
2017
The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model
Duvelisib is an orally active, dual inhibitor of phosphoinositide 3-kinase (PI3K)-δ and PI3K-γ which has shown clinical activity… 
2017
2017
Who stole my cholesterol ? A case report of night blindness and virtually absent serum
  • 2017
  • Corpus ID: 36795964
s of the 27th meeting of the Belgian Endocrine Society To cite this article: (2017) Abstracts of the 27th meeting of the Belgian… 
2016
2016
Abstract 376: Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines
2016
2016
NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies.
“We are pleased to provide funding to the NCCN ORP to further explore the clinical potential of duvelisib. We appreciate the…